Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection

Coronary Artery Disease (D Feldman, Section Editor)

DOI: 10.1007/s11936-014-0302-9

Cite this article as:
Singh, V. & Cohen, M.G. Curr Treat Options Cardio Med (2014) 16: 302. doi:10.1007/s11936-014-0302-9
Part of the following topical collections:
  1. Topical Collection on Coronary Artery Disease

Opinion statement

The estimated annual incidence of new and recurrent myocardial infarction (MI) in the U.S. is 715,000 events. Primary percutaneous coronary intervention (PCI) is the reperfusion strategy of choice in most patients with acute ST-elevation myocardial infarction (STEMI). Recent advances in percutaneous techniques and devices, including manual aspiration catheters and newer generation drug eluting stents and pharmacologic therapies, such as novel antiplatelets and anticoagulants have led to significant improvements in the acute and long-term outcomes for these patients. Implementation of community-wide systems directed to shorten treatment times tied to closely monitored quality improvement processes have led to further advances in STEMI care. Recent data suggests that transradial access for primary PCI is associated with improved outcomes. This contemporary review discusses the strategies for reperfusion, pharmacological therapy and stent selection process involved in STEMI.


Myocardial infarction Thrombolytic therapy Primary percutaneous coronary intervention Coronary stents 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Cardiovascular Division, and the Elaine and Sydney Sussman Cardiac Catheterization LaboratoryUniversity of Miami Hospital, Miller School of MedicineMiamiUSA

Personalised recommendations